Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate
Benzinga Newsdesk 9 months ago
BiotechHealth CareGeneral
Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.Verekitug also delivered clinically meaningful
- Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing.
- Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens.
- Verekitug was generally well tolerated, with a safety profile consistent with prior studies.
- Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study.
- Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions